nodes	percent_of_prediction	percent_of_DWPC	metapath
Valganciclovir—SLC6A14—NRF2 pathway—DNAJB1—liver cancer	0.00538	0.0661	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A2—liver cancer	0.00504	0.0619	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC40A1—liver cancer	0.00481	0.0591	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—liver cancer	0.00331	0.0406	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA3—liver cancer	0.00309	0.038	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA4—liver cancer	0.00283	0.0347	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA2—liver cancer	0.00276	0.0338	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA1—liver cancer	0.00266	0.0326	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—NFE2L2—liver cancer	0.00234	0.0288	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00229	0.0281	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00228	0.0279	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00228	0.0279	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TGFA—liver cancer	0.00224	0.0274	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GPX3—liver cancer	0.00224	0.0274	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SERPINA1—liver cancer	0.0022	0.0271	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00219	0.0268	CbGpPWpGaD
Valganciclovir—Gastrointestinal pain—Sorafenib—liver cancer	0.00203	0.00221	CcSEcCtD
Valganciclovir—Lymphadenopathy—Doxorubicin—liver cancer	0.00202	0.0022	CcSEcCtD
Valganciclovir—Phlebitis—Doxorubicin—liver cancer	0.002	0.00218	CcSEcCtD
Valganciclovir—Thrombophlebitis—Doxorubicin—liver cancer	0.00199	0.00217	CcSEcCtD
Valganciclovir—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00198	0.00216	CcSEcCtD
Valganciclovir—Diabetes mellitus—Doxorubicin—liver cancer	0.00198	0.00216	CcSEcCtD
Valganciclovir—Dermatitis exfoliative—Epirubicin—liver cancer	0.00197	0.00215	CcSEcCtD
Valganciclovir—Hepatic function abnormal—Doxorubicin—liver cancer	0.00197	0.00215	CcSEcCtD
Valganciclovir—Urticaria—Sorafenib—liver cancer	0.00197	0.00214	CcSEcCtD
Valganciclovir—Body temperature increased—Sorafenib—liver cancer	0.00196	0.00213	CcSEcCtD
Valganciclovir—Abdominal pain—Sorafenib—liver cancer	0.00196	0.00213	CcSEcCtD
Valganciclovir—Renal impairment—Epirubicin—liver cancer	0.00196	0.00213	CcSEcCtD
Valganciclovir—Eye pain—Doxorubicin—liver cancer	0.00191	0.00208	CcSEcCtD
Valganciclovir—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00186	0.00203	CcSEcCtD
Valganciclovir—Pain in extremity—Epirubicin—liver cancer	0.00186	0.00203	CcSEcCtD
Valganciclovir—Migraine—Epirubicin—liver cancer	0.00183	0.002	CcSEcCtD
Valganciclovir—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00183	0.00199	CcSEcCtD
Valganciclovir—Hypersensitivity—Sorafenib—liver cancer	0.00182	0.00199	CcSEcCtD
Valganciclovir—Renal impairment—Doxorubicin—liver cancer	0.00181	0.00197	CcSEcCtD
Valganciclovir—Asthenia—Sorafenib—liver cancer	0.00178	0.00193	CcSEcCtD
Valganciclovir—Pruritus—Sorafenib—liver cancer	0.00175	0.00191	CcSEcCtD
Valganciclovir—Ataxia—Epirubicin—liver cancer	0.00175	0.00191	CcSEcCtD
Valganciclovir—Blood creatinine increased—Epirubicin—liver cancer	0.00174	0.0019	CcSEcCtD
Valganciclovir—Dehydration—Epirubicin—liver cancer	0.00173	0.00189	CcSEcCtD
Valganciclovir—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.00172	0.00188	CcSEcCtD
Valganciclovir—Pain in extremity—Doxorubicin—liver cancer	0.00172	0.00188	CcSEcCtD
Valganciclovir—Dry skin—Epirubicin—liver cancer	0.00171	0.00186	CcSEcCtD
Valganciclovir—Abdominal pain upper—Epirubicin—liver cancer	0.0017	0.00185	CcSEcCtD
Valganciclovir—Migraine—Doxorubicin—liver cancer	0.0017	0.00185	CcSEcCtD
Valganciclovir—Hypokalaemia—Epirubicin—liver cancer	0.0017	0.00185	CcSEcCtD
Valganciclovir—Diarrhoea—Sorafenib—liver cancer	0.00169	0.00185	CcSEcCtD
Valganciclovir—Nasopharyngitis—Epirubicin—liver cancer	0.00167	0.00181	CcSEcCtD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—liver cancer	0.00166	0.0204	CbGpPWpGaD
Valganciclovir—Gastritis—Epirubicin—liver cancer	0.00165	0.00179	CcSEcCtD
Valganciclovir—Dizziness—Sorafenib—liver cancer	0.00164	0.00178	CcSEcCtD
Valganciclovir—Abdominal distension—Epirubicin—liver cancer	0.00162	0.00176	CcSEcCtD
Valganciclovir—Ataxia—Doxorubicin—liver cancer	0.00162	0.00176	CcSEcCtD
Valganciclovir—Blood creatinine increased—Doxorubicin—liver cancer	0.00161	0.00176	CcSEcCtD
Valganciclovir—Dysphagia—Epirubicin—liver cancer	0.00161	0.00175	CcSEcCtD
Valganciclovir—Influenza—Epirubicin—liver cancer	0.00161	0.00175	CcSEcCtD
Valganciclovir—Dehydration—Doxorubicin—liver cancer	0.0016	0.00174	CcSEcCtD
Valganciclovir—Eosinophilia—Epirubicin—liver cancer	0.00159	0.00174	CcSEcCtD
Valganciclovir—Dry skin—Doxorubicin—liver cancer	0.00158	0.00172	CcSEcCtD
Valganciclovir—Pancreatitis—Epirubicin—liver cancer	0.00158	0.00172	CcSEcCtD
Valganciclovir—Vomiting—Sorafenib—liver cancer	0.00157	0.00171	CcSEcCtD
Valganciclovir—Abdominal pain upper—Doxorubicin—liver cancer	0.00157	0.00171	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—GGT1—liver cancer	0.00157	0.0193	CbGpPWpGaD
Valganciclovir—Hypokalaemia—Doxorubicin—liver cancer	0.00157	0.00171	CcSEcCtD
Valganciclovir—Dermatitis—Sorafenib—liver cancer	0.00156	0.0017	CcSEcCtD
Valganciclovir—Headache—Sorafenib—liver cancer	0.00155	0.00169	CcSEcCtD
Valganciclovir—Bronchitis—Epirubicin—liver cancer	0.00155	0.00169	CcSEcCtD
Valganciclovir—Nasopharyngitis—Doxorubicin—liver cancer	0.00154	0.00168	CcSEcCtD
Valganciclovir—Pancytopenia—Epirubicin—liver cancer	0.00153	0.00166	CcSEcCtD
Valganciclovir—Gastritis—Doxorubicin—liver cancer	0.00153	0.00166	CcSEcCtD
Valganciclovir—Dysuria—Epirubicin—liver cancer	0.00151	0.00164	CcSEcCtD
Valganciclovir—Neutropenia—Epirubicin—liver cancer	0.00151	0.00164	CcSEcCtD
Valganciclovir—Abdominal distension—Doxorubicin—liver cancer	0.0015	0.00163	CcSEcCtD
Valganciclovir—Upper respiratory tract infection—Epirubicin—liver cancer	0.0015	0.00163	CcSEcCtD
Valganciclovir—Influenza—Doxorubicin—liver cancer	0.00149	0.00162	CcSEcCtD
Valganciclovir—Dysphagia—Doxorubicin—liver cancer	0.00149	0.00162	CcSEcCtD
Valganciclovir—Pollakiuria—Epirubicin—liver cancer	0.00149	0.00162	CcSEcCtD
Valganciclovir—Eosinophilia—Doxorubicin—liver cancer	0.00147	0.00161	CcSEcCtD
Valganciclovir—Nausea—Sorafenib—liver cancer	0.00147	0.0016	CcSEcCtD
Valganciclovir—Photosensitivity reaction—Epirubicin—liver cancer	0.00147	0.0016	CcSEcCtD
Valganciclovir—Pancreatitis—Doxorubicin—liver cancer	0.00146	0.00159	CcSEcCtD
Valganciclovir—Weight decreased—Epirubicin—liver cancer	0.00146	0.00159	CcSEcCtD
Valganciclovir—Hyperglycaemia—Epirubicin—liver cancer	0.00145	0.00158	CcSEcCtD
Valganciclovir—Pneumonia—Epirubicin—liver cancer	0.00144	0.00157	CcSEcCtD
Valganciclovir—Infestation—Epirubicin—liver cancer	0.00144	0.00156	CcSEcCtD
Valganciclovir—Infestation NOS—Epirubicin—liver cancer	0.00144	0.00156	CcSEcCtD
Valganciclovir—Bronchitis—Doxorubicin—liver cancer	0.00143	0.00156	CcSEcCtD
Valganciclovir—Pancytopenia—Doxorubicin—liver cancer	0.00141	0.00154	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—GSTP1—liver cancer	0.00141	0.0173	CbGpPWpGaD
Valganciclovir—Renal failure—Epirubicin—liver cancer	0.00141	0.00154	CcSEcCtD
Valganciclovir—Neuropathy peripheral—Epirubicin—liver cancer	0.00141	0.00153	CcSEcCtD
Valganciclovir—Stomatitis—Epirubicin—liver cancer	0.0014	0.00152	CcSEcCtD
Valganciclovir—Jaundice—Epirubicin—liver cancer	0.0014	0.00152	CcSEcCtD
Valganciclovir—Urinary tract infection—Epirubicin—liver cancer	0.0014	0.00152	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—HMOX1—liver cancer	0.00139	0.0171	CbGpPWpGaD
Valganciclovir—Neutropenia—Doxorubicin—liver cancer	0.00139	0.00152	CcSEcCtD
Valganciclovir—Dysuria—Doxorubicin—liver cancer	0.00139	0.00152	CcSEcCtD
Valganciclovir—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00138	0.00151	CcSEcCtD
Valganciclovir—Pollakiuria—Doxorubicin—liver cancer	0.00138	0.0015	CcSEcCtD
Valganciclovir—Haematuria—Epirubicin—liver cancer	0.00137	0.00149	CcSEcCtD
Valganciclovir—Photosensitivity reaction—Doxorubicin—liver cancer	0.00136	0.00148	CcSEcCtD
Valganciclovir—Hepatobiliary disease—Epirubicin—liver cancer	0.00136	0.00148	CcSEcCtD
Valganciclovir—Weight decreased—Doxorubicin—liver cancer	0.00135	0.00147	CcSEcCtD
Valganciclovir—Sinusitis—Epirubicin—liver cancer	0.00135	0.00147	CcSEcCtD
Valganciclovir—Hyperglycaemia—Doxorubicin—liver cancer	0.00134	0.00146	CcSEcCtD
Valganciclovir—Pneumonia—Doxorubicin—liver cancer	0.00134	0.00145	CcSEcCtD
Valganciclovir—Infestation—Doxorubicin—liver cancer	0.00133	0.00145	CcSEcCtD
Valganciclovir—Infestation NOS—Doxorubicin—liver cancer	0.00133	0.00145	CcSEcCtD
Valganciclovir—Renal failure—Doxorubicin—liver cancer	0.00131	0.00142	CcSEcCtD
Valganciclovir—Neuropathy peripheral—Doxorubicin—liver cancer	0.0013	0.00142	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—HGF—liver cancer	0.0013	0.0159	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTM1—liver cancer	0.0013	0.0159	CbGpPWpGaD
Valganciclovir—Haemoglobin—Epirubicin—liver cancer	0.0013	0.00141	CcSEcCtD
Valganciclovir—Stomatitis—Doxorubicin—liver cancer	0.00129	0.00141	CcSEcCtD
Valganciclovir—Jaundice—Doxorubicin—liver cancer	0.00129	0.00141	CcSEcCtD
Valganciclovir—Urinary tract infection—Doxorubicin—liver cancer	0.00129	0.00141	CcSEcCtD
Valganciclovir—Hepatitis—Epirubicin—liver cancer	0.00129	0.0014	CcSEcCtD
Valganciclovir—Haemorrhage—Epirubicin—liver cancer	0.00129	0.0014	CcSEcCtD
Valganciclovir—Pharyngitis—Epirubicin—liver cancer	0.00128	0.00139	CcSEcCtD
Valganciclovir—Urinary tract disorder—Epirubicin—liver cancer	0.00127	0.00139	CcSEcCtD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—liver cancer	0.00127	0.0156	CbGpPWpGaD
Valganciclovir—Oedema peripheral—Epirubicin—liver cancer	0.00127	0.00138	CcSEcCtD
Valganciclovir—Haematuria—Doxorubicin—liver cancer	0.00127	0.00138	CcSEcCtD
Valganciclovir—Connective tissue disorder—Epirubicin—liver cancer	0.00127	0.00138	CcSEcCtD
Valganciclovir—Urethral disorder—Epirubicin—liver cancer	0.00126	0.00138	CcSEcCtD
Valganciclovir—Hepatobiliary disease—Doxorubicin—liver cancer	0.00126	0.00137	CcSEcCtD
Valganciclovir—Sinusitis—Doxorubicin—liver cancer	0.00125	0.00136	CcSEcCtD
Valganciclovir—Visual impairment—Epirubicin—liver cancer	0.00124	0.00135	CcSEcCtD
Valganciclovir—Eye disorder—Epirubicin—liver cancer	0.0012	0.00131	CcSEcCtD
Valganciclovir—Tinnitus—Epirubicin—liver cancer	0.0012	0.00131	CcSEcCtD
Valganciclovir—Haemoglobin—Doxorubicin—liver cancer	0.0012	0.0013	CcSEcCtD
Valganciclovir—Cardiac disorder—Epirubicin—liver cancer	0.0012	0.0013	CcSEcCtD
Valganciclovir—Haemorrhage—Doxorubicin—liver cancer	0.00119	0.0013	CcSEcCtD
Valganciclovir—Hepatitis—Doxorubicin—liver cancer	0.00119	0.0013	CcSEcCtD
Valganciclovir—Pharyngitis—Doxorubicin—liver cancer	0.00118	0.00129	CcSEcCtD
Valganciclovir—Urinary tract disorder—Doxorubicin—liver cancer	0.00118	0.00128	CcSEcCtD
Valganciclovir—Oedema peripheral—Doxorubicin—liver cancer	0.00117	0.00128	CcSEcCtD
Valganciclovir—Connective tissue disorder—Doxorubicin—liver cancer	0.00117	0.00128	CcSEcCtD
Valganciclovir—Angiopathy—Epirubicin—liver cancer	0.00117	0.00127	CcSEcCtD
Valganciclovir—Urethral disorder—Doxorubicin—liver cancer	0.00117	0.00127	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00116	0.0143	CbGpPWpGaD
Valganciclovir—Immune system disorder—Epirubicin—liver cancer	0.00116	0.00127	CcSEcCtD
Valganciclovir—Mediastinal disorder—Epirubicin—liver cancer	0.00116	0.00126	CcSEcCtD
Valganciclovir—Chills—Epirubicin—liver cancer	0.00116	0.00126	CcSEcCtD
Valganciclovir—Arrhythmia—Epirubicin—liver cancer	0.00115	0.00125	CcSEcCtD
Valganciclovir—Visual impairment—Doxorubicin—liver cancer	0.00115	0.00125	CcSEcCtD
Valganciclovir—Alopecia—Epirubicin—liver cancer	0.00114	0.00124	CcSEcCtD
Valganciclovir—Mental disorder—Epirubicin—liver cancer	0.00113	0.00123	CcSEcCtD
Valganciclovir—Malnutrition—Epirubicin—liver cancer	0.00112	0.00122	CcSEcCtD
Valganciclovir—Eye disorder—Doxorubicin—liver cancer	0.00111	0.00121	CcSEcCtD
Valganciclovir—Tinnitus—Doxorubicin—liver cancer	0.00111	0.00121	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00111	0.0136	CbGpPWpGaD
Valganciclovir—Cardiac disorder—Doxorubicin—liver cancer	0.00111	0.0012	CcSEcCtD
Valganciclovir—Flatulence—Epirubicin—liver cancer	0.00111	0.0012	CcSEcCtD
Valganciclovir—Tension—Epirubicin—liver cancer	0.0011	0.0012	CcSEcCtD
Valganciclovir—Dysgeusia—Epirubicin—liver cancer	0.0011	0.0012	CcSEcCtD
Valganciclovir—Nervousness—Epirubicin—liver cancer	0.00109	0.00119	CcSEcCtD
Valganciclovir—Back pain—Epirubicin—liver cancer	0.00108	0.00118	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00108	0.0133	CbGpPWpGaD
Valganciclovir—Angiopathy—Doxorubicin—liver cancer	0.00108	0.00118	CcSEcCtD
Valganciclovir—Muscle spasms—Epirubicin—liver cancer	0.00108	0.00117	CcSEcCtD
Valganciclovir—Immune system disorder—Doxorubicin—liver cancer	0.00108	0.00117	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00108	0.0132	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00108	0.0132	CbGpPWpGaD
Valganciclovir—Mediastinal disorder—Doxorubicin—liver cancer	0.00107	0.00117	CcSEcCtD
Valganciclovir—Chills—Doxorubicin—liver cancer	0.00107	0.00116	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00107	0.0131	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00107	0.0131	CbGpPWpGaD
Valganciclovir—Arrhythmia—Doxorubicin—liver cancer	0.00107	0.00116	CcSEcCtD
Valganciclovir—Vision blurred—Epirubicin—liver cancer	0.00106	0.00115	CcSEcCtD
Valganciclovir—Alopecia—Doxorubicin—liver cancer	0.00105	0.00115	CcSEcCtD
Valganciclovir—Mental disorder—Doxorubicin—liver cancer	0.00104	0.00114	CcSEcCtD
Valganciclovir—Ill-defined disorder—Epirubicin—liver cancer	0.00104	0.00113	CcSEcCtD
Valganciclovir—Malnutrition—Doxorubicin—liver cancer	0.00104	0.00113	CcSEcCtD
Valganciclovir—Anaemia—Epirubicin—liver cancer	0.00104	0.00113	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00103	0.0127	CbGpPWpGaD
Valganciclovir—Agitation—Epirubicin—liver cancer	0.00103	0.00112	CcSEcCtD
Valganciclovir—Flatulence—Doxorubicin—liver cancer	0.00102	0.00111	CcSEcCtD
Valganciclovir—Tension—Doxorubicin—liver cancer	0.00102	0.00111	CcSEcCtD
Valganciclovir—Dysgeusia—Doxorubicin—liver cancer	0.00102	0.00111	CcSEcCtD
Valganciclovir—Malaise—Epirubicin—liver cancer	0.00101	0.0011	CcSEcCtD
Valganciclovir—Nervousness—Doxorubicin—liver cancer	0.00101	0.0011	CcSEcCtD
Valganciclovir—Vertigo—Epirubicin—liver cancer	0.00101	0.0011	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00101	0.0124	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00101	0.0124	CbGpPWpGaD
Valganciclovir—Leukopenia—Epirubicin—liver cancer	0.001	0.00109	CcSEcCtD
Valganciclovir—Back pain—Doxorubicin—liver cancer	0.001	0.00109	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000999	0.0123	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000999	0.0123	CbGpPWpGaD
Valganciclovir—Muscle spasms—Doxorubicin—liver cancer	0.000998	0.00109	CcSEcCtD
Valganciclovir—Cough—Epirubicin—liver cancer	0.000979	0.00107	CcSEcCtD
Valganciclovir—Vision blurred—Doxorubicin—liver cancer	0.000978	0.00106	CcSEcCtD
Valganciclovir—Convulsion—Epirubicin—liver cancer	0.000972	0.00106	CcSEcCtD
Valganciclovir—Hypertension—Epirubicin—liver cancer	0.000968	0.00105	CcSEcCtD
Valganciclovir—Ill-defined disorder—Doxorubicin—liver cancer	0.000963	0.00105	CcSEcCtD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00096	0.0118	CbGpPWpGaD
Valganciclovir—Anaemia—Doxorubicin—liver cancer	0.000959	0.00104	CcSEcCtD
Valganciclovir—Arthralgia—Epirubicin—liver cancer	0.000955	0.00104	CcSEcCtD
Valganciclovir—Agitation—Doxorubicin—liver cancer	0.000954	0.00104	CcSEcCtD
Valganciclovir—Anxiety—Epirubicin—liver cancer	0.000952	0.00104	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000948	0.00103	CcSEcCtD
Valganciclovir—Discomfort—Epirubicin—liver cancer	0.000943	0.00103	CcSEcCtD
Valganciclovir—Malaise—Doxorubicin—liver cancer	0.000936	0.00102	CcSEcCtD
Valganciclovir—Dry mouth—Epirubicin—liver cancer	0.000934	0.00102	CcSEcCtD
Valganciclovir—Vertigo—Doxorubicin—liver cancer	0.000932	0.00102	CcSEcCtD
Valganciclovir—Leukopenia—Doxorubicin—liver cancer	0.000929	0.00101	CcSEcCtD
Valganciclovir—Confusional state—Epirubicin—liver cancer	0.000923	0.001	CcSEcCtD
Valganciclovir—Anaphylactic shock—Epirubicin—liver cancer	0.000915	0.000997	CcSEcCtD
Valganciclovir—Oedema—Epirubicin—liver cancer	0.000915	0.000997	CcSEcCtD
Valganciclovir—Infection—Epirubicin—liver cancer	0.000909	0.00099	CcSEcCtD
Valganciclovir—Cough—Doxorubicin—liver cancer	0.000906	0.000986	CcSEcCtD
Valganciclovir—Convulsion—Doxorubicin—liver cancer	0.000899	0.000979	CcSEcCtD
Valganciclovir—Nervous system disorder—Epirubicin—liver cancer	0.000898	0.000977	CcSEcCtD
Valganciclovir—Thrombocytopenia—Epirubicin—liver cancer	0.000896	0.000976	CcSEcCtD
Valganciclovir—Hypertension—Doxorubicin—liver cancer	0.000896	0.000975	CcSEcCtD
Valganciclovir—Tachycardia—Epirubicin—liver cancer	0.000893	0.000973	CcSEcCtD
Valganciclovir—Skin disorder—Epirubicin—liver cancer	0.000889	0.000968	CcSEcCtD
Valganciclovir—Hyperhidrosis—Epirubicin—liver cancer	0.000885	0.000963	CcSEcCtD
Valganciclovir—Arthralgia—Doxorubicin—liver cancer	0.000884	0.000962	CcSEcCtD
Valganciclovir—Anxiety—Doxorubicin—liver cancer	0.000881	0.000959	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000877	0.000955	CcSEcCtD
Valganciclovir—Discomfort—Doxorubicin—liver cancer	0.000873	0.00095	CcSEcCtD
Valganciclovir—Anorexia—Epirubicin—liver cancer	0.000873	0.00095	CcSEcCtD
Valganciclovir—Dry mouth—Doxorubicin—liver cancer	0.000864	0.000941	CcSEcCtD
Valganciclovir—Hypotension—Epirubicin—liver cancer	0.000855	0.000931	CcSEcCtD
Valganciclovir—Confusional state—Doxorubicin—liver cancer	0.000854	0.00093	CcSEcCtD
Valganciclovir—Oedema—Doxorubicin—liver cancer	0.000847	0.000922	CcSEcCtD
Valganciclovir—Anaphylactic shock—Doxorubicin—liver cancer	0.000847	0.000922	CcSEcCtD
Valganciclovir—Infection—Doxorubicin—liver cancer	0.000841	0.000916	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000834	0.000908	CcSEcCtD
Valganciclovir—Nervous system disorder—Doxorubicin—liver cancer	0.000831	0.000904	CcSEcCtD
Valganciclovir—Thrombocytopenia—Doxorubicin—liver cancer	0.000829	0.000903	CcSEcCtD
Valganciclovir—Insomnia—Epirubicin—liver cancer	0.000828	0.000901	CcSEcCtD
Valganciclovir—Tachycardia—Doxorubicin—liver cancer	0.000827	0.0009	CcSEcCtD
Valganciclovir—Skin disorder—Doxorubicin—liver cancer	0.000823	0.000896	CcSEcCtD
Valganciclovir—Paraesthesia—Epirubicin—liver cancer	0.000822	0.000895	CcSEcCtD
Valganciclovir—Hyperhidrosis—Doxorubicin—liver cancer	0.000819	0.000891	CcSEcCtD
Valganciclovir—Dyspnoea—Epirubicin—liver cancer	0.000816	0.000888	CcSEcCtD
Valganciclovir—Somnolence—Epirubicin—liver cancer	0.000814	0.000886	CcSEcCtD
Valganciclovir—Anorexia—Doxorubicin—liver cancer	0.000807	0.000879	CcSEcCtD
Valganciclovir—Dyspepsia—Epirubicin—liver cancer	0.000806	0.000877	CcSEcCtD
Valganciclovir—Decreased appetite—Epirubicin—liver cancer	0.000796	0.000866	CcSEcCtD
Valganciclovir—Hypotension—Doxorubicin—liver cancer	0.000791	0.000862	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Epirubicin—liver cancer	0.00079	0.00086	CcSEcCtD
Valganciclovir—Fatigue—Epirubicin—liver cancer	0.000789	0.000859	CcSEcCtD
Valganciclovir—Constipation—Epirubicin—liver cancer	0.000783	0.000852	CcSEcCtD
Valganciclovir—Pain—Epirubicin—liver cancer	0.000783	0.000852	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000772	0.00084	CcSEcCtD
Valganciclovir—Insomnia—Doxorubicin—liver cancer	0.000766	0.000834	CcSEcCtD
Valganciclovir—Paraesthesia—Doxorubicin—liver cancer	0.000761	0.000828	CcSEcCtD
Valganciclovir—Dyspnoea—Doxorubicin—liver cancer	0.000755	0.000822	CcSEcCtD
Valganciclovir—Feeling abnormal—Epirubicin—liver cancer	0.000754	0.000821	CcSEcCtD
Valganciclovir—Somnolence—Doxorubicin—liver cancer	0.000753	0.00082	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Epirubicin—liver cancer	0.000749	0.000815	CcSEcCtD
Valganciclovir—Dyspepsia—Doxorubicin—liver cancer	0.000746	0.000812	CcSEcCtD
Valganciclovir—Decreased appetite—Doxorubicin—liver cancer	0.000736	0.000802	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000731	0.000796	CcSEcCtD
Valganciclovir—Fatigue—Doxorubicin—liver cancer	0.00073	0.000795	CcSEcCtD
Valganciclovir—Urticaria—Epirubicin—liver cancer	0.000727	0.000792	CcSEcCtD
Valganciclovir—Constipation—Doxorubicin—liver cancer	0.000724	0.000789	CcSEcCtD
Valganciclovir—Pain—Doxorubicin—liver cancer	0.000724	0.000789	CcSEcCtD
Valganciclovir—Abdominal pain—Epirubicin—liver cancer	0.000724	0.000788	CcSEcCtD
Valganciclovir—Body temperature increased—Epirubicin—liver cancer	0.000724	0.000788	CcSEcCtD
Valganciclovir—Feeling abnormal—Doxorubicin—liver cancer	0.000698	0.00076	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Doxorubicin—liver cancer	0.000693	0.000754	CcSEcCtD
Valganciclovir—Hypersensitivity—Epirubicin—liver cancer	0.000674	0.000734	CcSEcCtD
Valganciclovir—Urticaria—Doxorubicin—liver cancer	0.000673	0.000733	CcSEcCtD
Valganciclovir—Abdominal pain—Doxorubicin—liver cancer	0.00067	0.000729	CcSEcCtD
Valganciclovir—Body temperature increased—Doxorubicin—liver cancer	0.00067	0.000729	CcSEcCtD
Valganciclovir—Asthenia—Epirubicin—liver cancer	0.000657	0.000715	CcSEcCtD
Valganciclovir—Pruritus—Epirubicin—liver cancer	0.000648	0.000705	CcSEcCtD
Valganciclovir—Diarrhoea—Epirubicin—liver cancer	0.000626	0.000682	CcSEcCtD
Valganciclovir—Hypersensitivity—Doxorubicin—liver cancer	0.000624	0.000679	CcSEcCtD
Valganciclovir—Asthenia—Doxorubicin—liver cancer	0.000608	0.000662	CcSEcCtD
Valganciclovir—Dizziness—Epirubicin—liver cancer	0.000605	0.000659	CcSEcCtD
Valganciclovir—Pruritus—Doxorubicin—liver cancer	0.000599	0.000652	CcSEcCtD
Valganciclovir—Vomiting—Epirubicin—liver cancer	0.000582	0.000634	CcSEcCtD
Valganciclovir—Diarrhoea—Doxorubicin—liver cancer	0.00058	0.000631	CcSEcCtD
Valganciclovir—Dermatitis—Epirubicin—liver cancer	0.000577	0.000628	CcSEcCtD
Valganciclovir—Headache—Epirubicin—liver cancer	0.000573	0.000624	CcSEcCtD
Valganciclovir—Dizziness—Doxorubicin—liver cancer	0.00056	0.00061	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000551	0.00676	CbGpPWpGaD
Valganciclovir—Nausea—Epirubicin—liver cancer	0.000544	0.000592	CcSEcCtD
Valganciclovir—Vomiting—Doxorubicin—liver cancer	0.000539	0.000586	CcSEcCtD
Valganciclovir—Dermatitis—Doxorubicin—liver cancer	0.000534	0.000581	CcSEcCtD
Valganciclovir—Headache—Doxorubicin—liver cancer	0.000531	0.000578	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—TGFB1—liver cancer	0.000529	0.0065	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—ALB—liver cancer	0.000527	0.00647	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000526	0.00645	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—CYCS—liver cancer	0.000513	0.0063	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000511	0.00628	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000504	0.00619	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000504	0.00619	CbGpPWpGaD
Valganciclovir—Nausea—Doxorubicin—liver cancer	0.000503	0.000548	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000488	0.00599	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000476	0.00585	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000468	0.00574	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000468	0.00574	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000446	0.00548	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000442	0.00543	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—PPARA—liver cancer	0.000361	0.00443	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ALB—liver cancer	0.000268	0.00329	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—ALB—liver cancer	0.000249	0.00306	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—CYCS—liver cancer	0.000243	0.00298	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—RAF1—liver cancer	0.000242	0.00298	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—ALB—liver cancer	0.000231	0.00284	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—CYCS—liver cancer	0.000225	0.00277	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000211	0.00259	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000196	0.00241	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—PPARA—liver cancer	0.000171	0.00209	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—PPARA—liver cancer	0.000158	0.00194	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ALB—liver cancer	0.000127	0.00156	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ALB—liver cancer	0.000118	0.00144	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—RAF1—liver cancer	0.000115	0.00141	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—RAF1—liver cancer	0.000106	0.00131	CbGpPWpGaD
